ErbB2/Her2 antibody (pTyr1112)

Catalog No. ABIN1881304

This Rabbit Polyclonal antibody specifically detects ErbB2/Her2 in WB and DB. It exhibits reactivity toward Human and has been mentioned in 5+ publications.

Quick Overview for ErbB2/Her2 antibody (pTyr1112) (ABIN1881304)

Target: ErbB2/Her2 (Receptor tyrosine-protein kinase erbB-2 (ErbB2/Her2))

Reactivity: Human

Host: Rabbit

Clonality: Polyclonal

Conjugate: This ErbB2/Her2 antibody is un-conjugated

Application: Western Blotting (WB), Dot Blot (DB)

Clone: RB40063

Product Details anti-ErbB2/Her2 Antibody

Binding Specificity: pTyr1112

Purification: This antibody is purified through a protein A column, followed by peptide affinity purification.

Immunogen: This ErbB2 Antibody is generated from rabbits immunized with a KLH conjugated synthetic phosphopeptide corresponding to amino acid residues surrounding Y1112 of human ErbB2.

Isotype: Ig Fraction

Application Details

Application Notes: WB: 1:2000. DB: 1:500

Restrictions: For Research Use only

Handling

Format: Liquid

Buffer: Purified polyclonal antibody supplied in PBS with 0.09 % (W/V) sodium azide.

Preservative: Sodium azide

Precaution of Use: This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Storage: 4 °C,-20 °C

Expiry Date: 6 months

References for anti-ErbB2/Her2 antibody (ABIN1881304)

Mándoky, Géczi, Bodrogi, Tóth, Csuka, Kásler, Bak: "Clinical relevance of HER-2/neu expression in germ-cell testicular tumors." in: Anticancer research, Vol. 24, Issue 4, pp. 2219-24, (2004) (PubMed).

Contreras, Cobos, Lox: "Is the circulating urokinase plasminogen activator upregulated by the circulating p105 fraction of the HER-2/neu proto-oncogene in patients with cervical cancer?" in: Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis, Vol. 10, Issue 3, pp. 271-6, (2004) (PubMed).

Stephens, Hunter, Bignell, Edkins, Davies, Teague, Stevens, OMeara, Smith, Parker, Barthorpe, Blow, Brackenbury, Butler, Clarke, Cole, Dicks, Dike, Drozd, Edwards, Forbes, Foster, Gray, Greenman et al.: "Lung cancer: intragenic ERBB2 kinase mutations in tumours. ..." in: Nature, Vol. 431, Issue 7008, pp. 525-6, (2004) (PubMed).

Wang, Lien, Xia, Chen, Lo, Wang, Ali-Seyed, Lee, Bartholomeusz, Ou-Yang, Giri, Hung: "Binding at and transactivation of the COX-2 promoter by nuclear tyrosine kinase receptor ErbB-2." in: Cancer cell, Vol. 6, Issue 3, pp. 251-61, (2004) (PubMed).

Menendez, Vellon, Mehmi, Oza, Ropero, Colomer, Lupu: "Inhibition of fatty acid synthase (FAS) suppresses HER2/neu (erbB-2) oncogene overexpression in cancer cells." in: Proceedings of the National Academy of Sciences of the United States of America, Vol. 101, Issue 29, pp. 10715-20, (2004) (PubMed).

Target Details for ErbB2/Her2

Target: ErbB2/Her2 (Receptor tyrosine-protein kinase erbB-2 (ErbB2/Her2))

Alternative Name: ERBB2

Background: ErbB2 is a member of the epidermal growth factor (EGF) receptor family of receptor tyrosine kinases. This protein has no ligand binding domain of its own and therefore cannot bind growth factors. However, it does bind tightly to other ligand-bound EGF receptor family members to form a heterodimer, stabilizing ligand binding and enhancing kinase-mediated activation of downstream signalling pathways, such as those involving mitogen-activated protein kinase and phosphatidylinositol-3 kinase. Amplification and/or overexpression of this gene has been reported in numerous cancers, including breast and ovarian tumors.

Molecular Weight: 137910

NCBI Accession: NP_001005862, NP_004439

UniProt: P04626

Pathways: RTK Signaling, Fc-epsilon Receptor Signaling Pathway, EGFR Signaling Pathway, Neurotrophin Signaling Pathway, Skeletal Muscle Fiber Development